iBio

iBio Operating Cash Flow

The Operating Cash Flow of iBio (IBIO) as of Nov 19, 2026 is -23.22 M USD. In the previous year, Operating Cash Flow was -15.30 M USD — a change of 51.71% (lower).

Operating Cash Flow

-23.22 MUSD

YoY

51.71%

Last updated:

Operating Cash Flow of iBio is 2026 -23.22 M USD. Operating Cash Flow of iBio was 2025 -15.30 M USD. It decreases by 51.71% lower compared to the previous year.

The iBio Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
-13.98 M USD
Jan 1, 2020
-13.35 M USD
Jan 1, 2021
-30.06 M USD
Jan 1, 2022
-37.80 M USD
Jan 1, 2023
-30.44 M USD
Jan 1, 2024
-18.55 M USD
Jan 1, 2025
-15.30 M USD
Jan 1, 2026
-23.22 M USD
The iBio Operating Cash Flow history
YEAROperating Cash FlowYoY
-23.22 MUSD+51.71%
-15.30 MUSD-17.52%
-18.55 MUSD-39.04%
-30.44 MUSD-19.49%
-37.80 MUSD+25.74%
-30.06 MUSD+125.28%
-13.35 MUSD-4.51%
-13.98 MUSD+3.67%
-13.48 MUSD+2.41%
-13.16 MUSD+63.07%
-8.07 MUSD+70.84%
-4.73 MUSD+14.80%
-4.12 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iBio Stock analysis

What does iBio do? iBio, Inc. generates revenue through the commercialization of its plant-based protein expression technologies, which are used for developing vaccines and therapeutic proteins. The company's iBioLaunch technology and iBioModulator platform enable the production of biologics in hydroponically grown green plants, targeting fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of plasma-derived products. Clients and collaborators purchase product development and manufacturing services, leveraging iBio's transformative platform for biologics production. The firm focuses on both its own product candidates and providing services to external partners in the biopharmaceutical sector. iBio's business model centers on offering its proprietary technologies as a service to clients, with a focus on developing and manufacturing biologics through plant-based systems. The company's technologies are applicable across multiple therapeutic areas, including fibrotic disease treatments, vaccine development, and enzyme replacement therapies. By providing these services, iBio supports clients in creating advanced biopharmaceutical products without the need for traditional manufacturing infrastructure. The company's revenue streams include the sale of its iBioLaunch and iBioModulator platforms, as well as product development and manufacturing services for biopharmaceutical clients. These services are tailored to meet the needs of partners seeking efficient, scalable production methods for biologics. iBio's focus on plant-based production differentiates it in the market, appealing to clients looking for innovative approaches to biologic manufacturing. iBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iBio stock

Operating Cash Flow of iBio is -23.22 M USD in 2026.

Operating Cash Flow of iBio changed from -15.30 M USD to -23.22 M USD, representing a 51.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow iBio since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's iBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — iBio

All Key Metrics — iBio